Login to Your Account

F2G's $30M Round to Support New F3 Antifungal Program

By Catherine Shaffer
Staff Writer

Wednesday, September 12, 2012
F2G Ltd., of Manchester, UK, will use a new $30 million equity financing round to jump a lead candidate from its F3 series of preclinical compounds into first-in-man studies.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription